GENB Generate Biomedicines, Inc.
$15.72▲ +2.14%
Healthcare
Other
After hours
$15.69▼ -0.20%
Sep 11, 7:46 PM ET
Volume 666.0K
Avg Volume (10D) 1.36M
Key Metrics & Fundamentals
Market Cap
$2.02B
P/E Ratio
–
Div Yield
–%
52W Range
11.00 - 22.67
% vs 50 MA
3.67%
% vs 200 MA
–%
RSI-14
50.1
MACD Histogram
-0.1600
Beta (1Y vs SPY)
1.47
Free Cash Flow
-$58.88M
Gross Rev
$6.31M
Gross Profit
$6.31M
EBITDA
-$63.76M
COGS
–
Operating Exp
$77.93M
Operating Income
-$71.61M
EBIT
-$71.61M
Pretax Income
-$67.20M
Net Income
-$67.26M
EPS (Diluted)
-0.52
Price & Volume History
Loading chart…
Recent News
AI Could Eventually Crack Cancer and Drug Discovery, Says Arm CEO — But This Is What’s Holding It Back
Benzinga · Sep 8, 2026 2:36 PM
Generate Biomedicines Inc. to Participate in September Investor Conferences
GlobeNewswire · Sep 8, 2026 11:09 AM
How Nvidia’s Investment Juggernaut Can Jump from Big to Enormous
Barrons.com · Sep 7, 2026 2:07 PM
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
BioPharma Dive · Aug 28, 2026 11:59 AM
EXCLUSIVE: Nvidia GPUs Are Essential—But They Won't Decide Who Wins AI Drug Discovery, Generate CTO Says
Benzinga · Aug 27, 2026 11:31 PM
Cathie Wood Sends a $20 Million Signal on Broadcom Stock
GuruFocus.com · Aug 27, 2026 7:18 PM
Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns
Simply Wall St. · Aug 26, 2026 10:16 PM
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Proactive · Aug 25, 2026 3:10 PM
Nvidia Holds More Than 122 Million Shares of SPCX Stock After Q2. Barchart Data Shows It’s Making a High-Upside Bet.
Barchart · Aug 18, 2026 6:56 PM
Two Positions Make Up 80% of Nvidia's $63.4 Billion Portfolio
GuruFocus.com · Aug 17, 2026 4:12 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See GENB's money flow as a full page
Social Sentiment
Avg +0.70 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.